Insider Shareholders with Direct Ownership of Xenon Pharmaceuticals Inc. (XENE)
This section provides a comprehensive overview of the insiders with direct ownership of Xenon Pharmaceuticals Inc. (XENE). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
Xenon Pharmaceuticals Inc. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
|
Frank A Holler
Director |
39,094 | 17,482 | 143,653 $6.24 Million | 2 |
May 27, 2021
Reduced 5.58%
|
|
Michael R Hayden
Director |
8,644 | 0 | 116,206 $5.05 Million | 2 |
May 18, 2021
Added 2.92%
|
|
Michael M Tarnow
Director |
18,517 | 10,288 | 77,942 $3.39 Million | 3 |
May 18, 2021
Added 6.19%
|
| 13,578 | 0 | 74,225 $3.22 Million | 4 |
Dec 19, 2023
Added 4.5%
|
|
|
Bvf Partners L P
> 10% Shareholder |
0 | 2,437,000 | 59,464 $2.58 Million | 1 |
Mar 27, 2018
Reduced 80.01%
|
|
Ian Mortimer
PRESIDENT, CEO & INTERIM CFO |
149,340 | 124,038 | 31,302 $1.36 Million | 10 |
Oct 01, 2025
Reduced 44.4%
|
| 0 | 25,000 | 25,000 $1.09 Million | 1 |
Aug 24, 2023
Reduced 50.0%
|
|
| 27,159 | 25,102 | 23,573 $1.02 Million | 9 |
Nov 22, 2024
Reduced 7.96%
|
|
|
James R. Empfield
EVP, Drug Discovery |
132,500 | 132,500 | 10,000 $434,400 | 6 |
Aug 12, 2022
Reduced 68.63%
|
|
Sherrington Robin
EVP, Strategy & Innovation |
114,254 | 122,652 | 8,398 $364,809 | 11 |
Mar 07, 2024
Reduced 42.15%
|
| 5,144 | 13,003 | 7,141 $310,205 | 3 |
Jun 05, 2025
Reduced 0.04%
|
|
| 259,666 | 463,852 | 6,000 $260,640 | 18 |
Jun 01, 2023
Reduced 80.17%
|
|
|
Christopher Von Seggern
Chief Commercial Officer |
4,000 | 0 | 4,000 $173,760 | 1 |
Dec 06, 2021
Added 50.0%
|
|
Sherry Aulin
Chief Financial Officer |
43,982 | 43,982 | 0 $0 | 4 |
Dec 18, 2024
Reduced 100.0%
|
| 3,500 | 3,500 | 0 $0 | 2 |
Mar 08, 2024
Reduced 100.0%
|
|
|
Christopher John Kenney
Chief Medical Officer |
700 | 700 | 0 $0 | 2 |
Mar 24, 2023
Reduced 100.0%
|